Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours

Clinical and Translational Oncology

Volumn 16, Issue 3, 2014, Pages 322-329

  Duran I ^a,k   Garzon C ^b   Sanchez A ^c   Garcia Carbonero I ^d   Perez Gracia J L ^e   Segui Palmer M A ^f   Wei, R ^g   Restovic, G ^h   Gasquet, J A ⁱ   Gutierrez L ^j  

^a Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f Servicio de Oncología Médica   (Spain)

^g AMGEN INC   (United States)

^h Bayer HealthCare   (Spain)

ⁱ Amgen SA   (Spain)

^j Walgreens Health Services   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

Bone metastases; Costs study; Health care resource utilisation; Skeletal related events; SRE

Indexed keywords

ADULT; AGED; ARTICLE; BONE DISEASE; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EMERGENCY WARD; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LENGTH OF STAY; LIFE EXPECTANCY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; NURSING HOME PERSONNEL; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATHOLOGIC FRACTURE; PROSPECTIVE STUDY; PROSTATE CANCER; RETROSPECTIVE STUDY; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION; SPINE FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SPAIN;

EID: 84896736732     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1077-2     Document Type: Article

References (22)

1. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(Suppl 4):14-27.
2. Coleman RE. The role of bisphosphonates in breast cancer. Breast. 2004;13(Suppl 1):S19-28.
3. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341-7.
4. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6(2):161-71.
5. LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol. 2001;28(4 Suppl 11):22-7.
6. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165-76.
7. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009;9:272.
8. Saad F, Chen YM, Gleason DM, Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer. 2007;5(6):390-6.
9. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer. 2004;6(3):170-4.
10. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36-43.
11. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129-35.
12. Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol. 1993;24(Suppl 2):118-21.
13. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164-75.
14. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005;16(4):579-84.
15. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 2007;4(2):92-100.
16. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl). 2010;19(6):755-60.
17. Bahl A, Hoefeler H, Duran I, Hechmati G, Garzon-Rodriguez C, Lüftner D, et al. Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): results of a prospective multinational observational study. J Clin Oncol. 2011;29:e16523 (suppl; abstr).
18. Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, et al. Cost of skeletal-related events (SREs) in patients with bone metastases to solid tumours based on the health resource utilisation (HRU) collected in a prospective European multinational observational study. Value Health. 2011;14(7):A455 (PCN115).
19. Oblikue Consulting. eSalud - información económica del sector sanitario. Base de datos de costes sanitarios. 2012. http://www.oblikue. com/bddcostes. Accessed 30 May 2012.
20. Gralow J, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage. 2007;33(4):462-72.
21. Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011;129(2):495-503.
22. Norgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162-7.